세계의 SGLT2 억제제 시장 : 산업규모, 점유율, 동향, 기회, 예측, 약제별, 적응증별, 지역별, 경쟁별(2020-2030년)
SGLT2 Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug (Jardiance, Farmiga, Inpefa, Invokana, Others), By Indication (Type 2 Diabetes, Cardiovascular, Others), By Region and Competition, 2020-2030F
상품코드:1797134
리서치사:TechSci Research
발행일:2025년 08월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 SGLT2 억제제 시장은 2024년에 153억 7,000만 달러로 평가되었고, CAGR 5.90%로 성장할 전망이며, 2030년에는 214억 4,000만 달러에 이를 것으로 예측됩니다.
이러한 경구용 항당뇨병제는 신장을 통한 포도당 배설을 촉진하여 혈당 수치를 낮추는 능력과 함께 체중 감소 및 심혈관 위험 감소와 같은 추가적인 이점을 제공하기 때문에 선호되는 치료 옵션으로 부상했습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
153억 7,000만 달러
시장 규모 : 2030년
214억 4,000만 달러
CAGR : 2025-2030년
5.90%
급성장 부문
자디언스
최대 시장
북미
당뇨병 발병률 증가와 함께 혈당 조절 불량과 관련된 합병증에 대한 인식이 높아지면서 효과적이고 내약성이 우수한 치료 옵션을 요구하는 환자군이 확대되고 있습니다. 강력한 성장 전망에도 불구하고 높은 치료 비용, 엄격한 규제 요건, 요로 감염 및 케톤산증과 같은 부작용에 대한 우려와 같은 도전 과제들이 시장 확장을 어느 정도 제한할 수 있습니다.
주요 시장 성장 촉진요인
의료 산업 성장
주요 시장 과제
치료비 급등
주요 시장 동향
당뇨병 유병률 상승
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 COVID-19가 세계의 SGLT2 억제제 시장에 미치는 영향
제5장 세계의 SGLT2 억제제 시장 전망
시장 규모와 예측
금액별
시장 점유율 및 예측
약제별(자디언스, 파미가, 임페파, 인보카나, 기타)
적응증별(2형 당뇨병, 심혈관 질환, 기타)
지역별
기업별(2024년)
시장 맵
제6장 북미의 SGLT2 억제제 시장 전망
시장 규모와 예측
시장 점유율 및 예측
북미 : 국가별 분석
미국
멕시코
캐나다
제7장 유럽의 SGLT2 억제제 시장 전망
시장 규모와 예측
시장 점유율 및 예측
유럽 : 국가별 분석
프랑스
독일
영국
이탈리아
스페인
제8장 아시아태평양의 SGLT2 억제제 시장 전망
시장 규모와 예측
시장 점유율 및 예측
아시아태평양 : 국가별 분석
중국
인도
한국
일본
호주
제9장 남미의 SGLT2 억제제 시장 전망
시장 규모와 예측
시장 점유율 및 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 SGLT2 억제제 시장 전망
시장 규모와 예측
시장 점유율 및 예측
중동 및 아프리카 : 국가별 분석
남아프리카
사우디아라비아
아랍에미리트(UAE)
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
합병과 인수
제품 출시
최근 동향
제13장 혼란: 분쟁, 유행, 무역 장벽
제14장 세계의 SGLT2 억제제 시장 : SWOT 분석
제15장 Porter's Five Forces 분석
업계 내 경쟁
신규 진입의 가능성
공급자의 힘
고객의 힘
대체품의 위협
제16장 경쟁 구도
Boehringer Ingelheim International GmbH
AstraZeneca
Merck & Co., Inc.
Janssen Pharmaceuticals, Inc.
TheracosBio, LLC
Lexicon Pharmaceuticals, Inc.
Eli Lilly and Company
Bristol-Myers Squibb Company
Glenmark Pharmaceuticals Ltd.
제17장 전략적 제안
제18장 기업 소개와 면책사항
HBR
영문 목차
영문목차
Global SGLT2 Inhibitors Market was valued at USD 15.37 Billion in 2024 and is expected to reach USD 21.44 Billion by 2030 with a CAGR of 5.90%. These oral antidiabetic agents have emerged as a preferred therapeutic option due to their ability to lower blood glucose levels by promoting glucose excretion through the kidneys, while also offering additional benefits such as weight loss and cardiovascular risk reduction.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 15.37 Billion
Market Size 2030
USD 21.44 Billion
CAGR 2025-2030
5.90%
Fastest Growing Segment
Jardiance
Largest Market
North America
Rising diabetes incidence, coupled with growing awareness of the complications associated with poor glycemic control, has led to an expanding patient pool demanding effective and well-tolerated treatment options. Despite robust growth prospects, challenges such as high treatment costs, stringent regulatory requirements, and concerns about side effects including urinary tract infections and ketoacidosis may constrain market expansion to some extent.
Key Market Drivers
Growth in Healthcare Industry
The rapid expansion of the global healthcare industry is a significant catalyst driving growth in the SGLT2 inhibitors market. The global healthcare industry generates annual sales exceeding USD 4 trillion. Its largest and most lucrative segments are pharmaceuticals and biotechnology, with revenues approaching USD 850 billion, followed by medical technology and diagnostics, which exceed USD 400 billion. Increasing investments in healthcare infrastructure, advancements in medical technology, and improved access to quality care are collectively enhancing the diagnosis and management of chronic diseases such as type 2 diabetes mellitus (T2DM), which is the primary indication for SGLT2 inhibitors.
Rising healthcare expenditure, particularly in emerging economies, is enabling broader patient access to innovative therapies, including SGLT2 inhibitors. A report from the World Health Organization (WHO) indicates that global health expenditure continued to rise in 2021, the second year of the pandemic, reaching USD 9.8 trillion equivalent to 10.3% of global GDP. This increase was primarily driven by higher government funding and out-of-pocket expenses. Furthermore, the growing emphasis on early diagnosis and comprehensive disease management programs is boosting prescription rates for these novel antidiabetic agents.
Key Market Challenges
High Cost of Therapy
One of the primary challenges facing the global SGLT2 inhibitors market is the high cost of therapy, which can limit patient access and hinder widespread adoption. Despite their proven clinical benefits, SGLT2 inhibitors are often priced at a premium compared to traditional antidiabetic medications, placing a significant financial burden on both patients and healthcare systems, particularly in low- and middle-income countries.
The elevated cost is driven by factors such as complex manufacturing processes, ongoing research and development expenditures, and patent protections that limit the availability of lower-cost generic alternatives. This pricing barrier may result in restricted insurance coverage or reimbursement limitations, thereby reducing affordability for a large segment of the diabetic population.
Key Market Trends
Rising Prevalence of Diabetes
The escalating prevalence of diabetes, particularly type 2 diabetes mellitus (T2DM), is a critical trend shaping the trajectory of the global SGLT2 inhibitors market. According to recent epidemiological data, the number of individuals diagnosed with diabetes continues to rise worldwide, driven by factors such as sedentary lifestyles, urbanization, obesity, and aging populations.
Diabetes statistics highlight the increasing global burden of the disease on individuals, families, and nations. According to the latest International Diabetes Federation (IDF) Diabetes Atlas (2025), 11.1% or 1 in 9 of adults aged 20-79 are living with diabetes, with more than 40% unaware of their condition. This growing patient pool has intensified the demand for effective and innovative therapeutic options, positioning SGLT2 inhibitors as a preferred class of oral antidiabetic agents. Their ability to improve glycemic control, coupled with additional benefits such as cardiovascular and renal protection, has enhanced their clinical appeal and expanded their use.
Key Market Players
Boehringer Ingelheim International GmbH
AstraZeneca
Merck & Co., Inc.
Janssen Pharmaceuticals, Inc.
TheracosBio, LLC
Lexicon Pharmaceuticals, Inc.
Eli Lilly and Company
Bristol-Myers Squibb Company
Glenmark Pharmaceuticals Ltd.
Report Scope
In this report, the Global SGLT2 Inhibitors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
SGLT2 Inhibitors Market, By Drug:
Jardiance
Farmiga
Inpefa
Invokana
Others
SGLT2 Inhibitors Market, By Indication:
Type 2 Diabetes
Cardiovascular
Others
SGLT2 Inhibitors Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global SGLT2 Inhibitors Market.
Available Customizations:
Global SGLT2 Inhibitors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. Impact of COVID-19 on Global SGLT2 Inhibitors Market
5. Global SGLT2 Inhibitors Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug (Jardiance, Farmiga, Inpefa, Invokana, Others)
5.2.2. By Indication (Type 2 Diabetes, Cardiovascular, Others)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. North America SGLT2 Inhibitors Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug
6.2.2. By Indication
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States SGLT2 Inhibitors Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug
6.3.1.2.2. By Indication
6.3.2. Mexico SGLT2 Inhibitors Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug
6.3.2.2.2. By Indication
6.3.3. Canada SGLT2 Inhibitors Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug
6.3.3.2.2. By Indication
7. Europe SGLT2 Inhibitors Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug
7.2.2. By Indication
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France SGLT2 Inhibitors Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug
7.3.1.2.2. By Indication
7.3.2. Germany SGLT2 Inhibitors Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug
7.3.2.2.2. By Indication
7.3.3. United Kingdom SGLT2 Inhibitors Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug
7.3.3.2.2. By Indication
7.3.4. Italy SGLT2 Inhibitors Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug
7.3.4.2.2. By Indication
7.3.5. Spain SGLT2 Inhibitors Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug
7.3.5.2.2. By Indication
8. Asia Pacific SGLT2 Inhibitors Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug
8.2.2. By Indication
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China SGLT2 Inhibitors Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug
8.3.1.2.2. By Indication
8.3.2. India SGLT2 Inhibitors Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug
8.3.2.2.2. By Indication
8.3.3. South Korea SGLT2 Inhibitors Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug
8.3.3.2.2. By Indication
8.3.4. Japan SGLT2 Inhibitors Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug
8.3.4.2.2. By Indication
8.3.5. Australia SGLT2 Inhibitors Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug
8.3.5.2.2. By Indication
9. South America SGLT2 Inhibitors Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug
9.2.2. By Indication
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil SGLT2 Inhibitors Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug
9.3.1.2.2. By Indication
9.3.2. Argentina SGLT2 Inhibitors Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug
9.3.2.2.2. By Indication
9.3.3. Colombia SGLT2 Inhibitors Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug
9.3.3.2.2. By Indication
10. Middle East and Africa SGLT2 Inhibitors Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug
10.2.2. By Indication
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa SGLT2 Inhibitors Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug
10.3.1.2.2. By Indication
10.3.2. Saudi Arabia SGLT2 Inhibitors Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug
10.3.2.2.2. By Indication
10.3.3. UAE SGLT2 Inhibitors Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug
10.3.3.2.2. By Indication
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Disruptions: Conflicts, Pandemics and Trade Barriers
